Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Selumetinib
Drug ID BADD_D02594
Description Activation of the Raf-MEK-ERK signaling pathway is known to be implemented in several types of malignancies, thus, mitogen-activated protein kinase kinase (MEK) inhibitors such as selumetinib are important tools that can target the problematic overactivity of this pathway.[A193611] Results from clinical trials investigating earlier developed MEK inhibitors were underwhelming.[A193611] However, selumetinib demonstrated impressive efficacy and tolerability in Phase I trials, leading to its continued investigation for the treatment of various types of tumors in Phase II trials.[A193611] Currently, the novel MEK 1 / 2 inhibitor, selumetinib, is approved solely for the treatment of Neurofibromatosis type 1 (NF-1) in a limited age group. NF-1 is considered rare with an estimated incidence of 1/3000 individuals.[A193608] It is a genetic, autosomal dominant condition resulting from mutations of the NF1 gene, which can lead to various complications including the development of multiple tumors in the nervous system.[A193533,A193608] Some patients with this disorder develop plexiform neurofibromas (PN); however, this is considered to be relatively uncommon compared to other variants of NF-1.[A193608] Luckily, the use of selumetinib in patients with NF-1 has shown efficacy in shrinking associated tumors and is linked to other positive clinical outcomes.[A193533]
Indications and Usage Although selumetinib has been investigated for the treatment of several types of cancer, it is currently only indicated for the treatment of neurofibromatosis type 1 (NF1) in patients ≥2 years who have symptomatic, inoperable plexiform neurofibromas (PN).[A193611,L12852,L12969]
Marketing Status approved; investigational
ATC Code L01EE04
DrugBank ID DB11689
KEGG ID D09666
MeSH ID C517975
PubChem ID 10127622
TTD Drug ID D0T5DP
NDC Product Code 67651-0344; 0310-0610; 0310-0625; 67651-0343
UNII 6UH91I579U
Synonyms AZD 6244 | AZD6244 | AZD-6244 | selumetinib | ARRY 142886 | ARRY142886 | ARRY-142886
Chemical Information
Molecular Formula C17H15BrClFN4O3
CAS Registry Number 606143-52-6
SMILES CN1C=NC2=C1C=C(C(=C2F)NC3=C(C=C(C=C3)Br)Cl)C(=O)NOCCO
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal discomfort07.01.06.0010.000381%Not Available
Abdominal pain07.01.05.0020.000392%
Abdominal pain upper07.01.05.0030.000168%
Acne23.02.01.0010.001063%Not Available
Alopecia23.02.02.0010.000660%
Anaemia01.03.02.0010.000168%
Asthenia08.01.01.0010.000224%Not Available
Back pain15.03.04.0050.000112%
Dermatitis23.03.04.0020.000168%Not Available
Dermatitis acneiform23.02.01.0040.000828%
Diarrhoea07.02.01.0010.000716%
Dry skin23.03.03.0010.000168%
Gastrooesophageal reflux disease07.02.02.0030.000246%
Hair colour changes23.02.06.0010.000168%
Hyperphosphataemia14.04.03.0070.000246%
Hypertension24.08.02.0010.000112%
Impaired healing08.03.02.0010.000112%Not Available
Ingrowing nail23.02.05.0110.000112%Not Available
Insomnia19.02.01.002; 17.15.03.0020.000168%
Menstrual disorder21.01.01.0040.000381%Not Available
Muscular weakness15.05.06.001; 17.05.03.0050.000246%
Myalgia15.05.02.0010.000168%
Nausea07.01.07.0010.000795%
Neoplasm16.16.02.0010.000168%Not Available
Neutropenia01.02.03.0040.000392%Not Available
Oedema peripheral14.05.06.011; 08.01.07.007; 02.05.04.0070.000112%
Pollakiuria20.02.02.0070.000414%
Proteinuria20.02.01.0110.000112%
Pruritus23.03.12.0010.000392%
Pyrexia08.05.02.0030.000168%
The 1th Page    1 2    Next   Last    Total 2 Pages